Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$340,287
-$19,381 QoQ
Shares Held
7,934
-3.3% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ascent Group, LLC holds $3,297,609 across 6 Biotechnology names. EXEL ranks #2 (10.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,410 | $1,969,239 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
7,934 | $340,287 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
377 | $291,284 | |
| 4 | BCAX |
Bicara Therapeutics Inc.
|
14,152 | $281,483 | |
| 5 | ANAB |
Anaptysbio, Inc
|
5,622 | $207,863 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
627 | $207,453 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $340,287 | 7,934 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $359,668 | 8,206 | Shares | Other | 2026-01-20 | |
| 2025-09-30 | $352,535 | 8,536 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||